

Curriculum Viata



Ass. Prof. Dr. Nadhir Najim Abdullah Jafar

Department of Pharmacy, Al-Mustaqbal University College, Iraq

Tel: +964 7800433615

E-Mail: nathernajim1@gmail.com

Scopus Author ID: 50261905400,

Researcher ID: L-5323-2014,

<https://www.pubfacts.com/author/Nadhir+N+Jafar>

<https://www.mendeley.com/profiles/nadhir-jafar2/> H-index:3, citation:21

<https://orcid.org/0000-0003-2279-8781>

<https://loop.frontiersin.org/people/384326/overview>

Date of birth: 18.08.1959

Place of birth: Basrah, Iraq

Qualification:: B.Sc., Chemistry, University of Sulaimani, 1979-1980
M.Sc., Applied Organic chemistry, Jordan University of Science and Technology, 2001-2002
Ph.D., Organic chemistry, University of Babylon, Iraq/ 2012

Thesis: **M.Sc.:** Synthesis, Characterization and photocrosslinking of Negative Photoresist Polymers.

Ph.D.: Synthesis and Structural Assignment of Drug "INDOMETHACIN"

under supervision of Professor Najim Al-masoudi.

Academic positions: *Assis. Lecturer, Chemistry, Babylon Uni., 2003-2006

*Lecturer, Organic chemistry, Babylon Uni., 2006-2009

*Assis. Professor, Organic Chemistry, Babylon Uni., 2012- till now.

*2017 –till now faculty member in Dep. Of Pharmacy/ Al-Mustaqbal University College.

Publications: **26** published papers.

Teaching: *Teaching of organic courses (B.Sc, M.Sc. and Ph.D.): In Science College. Dep. Of Chemistry and Dep. of Pharmacy:
Mechanism of organic chemistry, Stereochemistry, Organic synthesis, Pericyclic reactions, Chemistry of Heterocyclic chemistry..

Scientific activities:

* Member of the American Chem. Soc.

* Member of German Chemical Soc. (GDH)

* Member of the Iraqi National Journal of Chemistry

*Reviewers of several international journals.

***Patent #5356 in 3-5-2018** "Synthesis of new co-polymers as drug delivery"

Supervision: 2 Ph.D. theses (Iraq)

3 M.Sc. theses (Iraq)

Current work:

- Early Tumor Diagnosis by New Fluorescence Imaging Agents.
- Synthesis of new organic as new inhibitors anticancer as kinesin Eg5 inhibitors.
- Designing of new anti-HIV and anti-hepatitis C (HCV) agents.